<DOC>
	<DOCNO>NCT02392702</DOCNO>
	<brief_summary>This two-part study ass , healthy volunteer , fast fed condition , sequential manner , safety , tolerability pharmacokinetics ( PK ) profile single dose C-10355 C-10358 single ascending dos select compound compare single dose Kalydeco® .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability PK C-10355 C-10358 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy adult 18 50 year age , inclusive Body weight ≥ 50 kg BMI within range 18 30 kg/m2 , inclusive , screen History clinically significant central nervous system ( eg , seizure ) , cardiac , pulmonary , metabolic , renal ( include nephrolithiasis ) , hepatic , include history Gilbert 's syndrome gastrointestinal ( GI ) condition PR interval ≥ 220 msec QRS duration ≥ 120 msec QTcF interval &gt; 450 msec obtain screen visit prior first dose study drug Liver function test great upper limit normal . Positive blood screen human immunodeficiency virus ( HIV antibody ) , hepatitis B virus surface antigen , hepatitis C virus antibody screen Urinalysis positive great trace blood , protein glucose A positive screen alcohol , drug abuse , tobacco use . Inability comply food beverage restriction study participation . Donation blood collection acute loss blood prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Subjects</keyword>
	<keyword>Safety/Efficacy Study</keyword>
	<keyword>Randomized</keyword>
	<keyword>Open Label</keyword>
</DOC>